In Vitro And In Vivo Synergistic Efficacy Of Ceritinib Combined With Programmed Cell Death Ligand‐1 Inhibitor In Anaplastic Lymphoma Kinase‐Rearranged Non‐Small‐Cell Lung Cancer

Cancer Science
02 Jul, 2020 ,

Ping Du conducted a study to assess the tumor killing effect of ceritinib plus PD‐L1 inhibitor in vitro by quantitative RT‐PCR, flow cytometry, ELISA, western blot analysis, PBMC coculture system, and plasmid and transfection experiments. The researchers concluded that Ceritinib and PD‐L1 inhibitor combined produced a synergistic antineoplastic efficacy in vitro and in vivo, which provides a key insight and proof of principle for evaluating CER plus PD‐L1 blockade as combination therapy in clinical therapeutic practice.